@article {10478, title = {A Teenager with Sudden Unilateral Breast Enlargement.}, journal = {J Pediatr}, volume = {182}, year = {2017}, month = {2017 03}, pages = {394}, keywords = {Bullying, Child, Gynecomastia, Hematoma, Humans, Male, Wounds, Nonpenetrating}, issn = {1097-6833}, doi = {10.1016/j.jpeds.2016.11.044}, author = {Pellegrin, Maria Chiara and Naviglio, Samuele and Cattaruzzi, Elisabetta and Barbi, Egidio and Ventura, Alessandro} } @article {7757, title = {A case of Rubinstein-Taybi syndrome associated with growth hormone deficiency in childhood.}, journal = {Clin Endocrinol (Oxf)}, volume = {83}, year = {2015}, month = {2015 Sep}, pages = {437-9}, issn = {1365-2265}, doi = {10.1111/cen.12748}, author = {Tornese, Gianluca and Marzuillo, Pierluigi and Pellegrin, Maria Chiara and Germani, Claudio and Faleschini, Elena and Zennaro, Floriana and Grandone, Anna and Miraglia Del Giudice, Emanuele and Perrone, Laura and Ventura, Alessandro} } @article {7708, title = {Effect of Thalidomide on Clinical Remission in Children and Adolescents with Ulcerative Colitis Refractory to Other Immunosuppressives: Pilot Randomized Clinical Trial.}, journal = {Inflamm Bowel Dis}, volume = {21}, year = {2015}, month = {2015 Aug}, pages = {1739-49}, abstract = {

BACKGROUND: In a randomized controlled trial, thalidomide has shown to be effective in refractory Crohn{\textquoteright}s disease in children. This pilot study aimed at evaluating thalidomide in refractory pediatric ulcerative colitis (UC).

METHODS: Double-blind, placebo-controlled randomized clinical trial on thalidomide 1.5 to 2.5 mg/kg/day in children with active UC despite multiple immunosuppressive treatments. In an open-label extension, nonresponders to placebo received thalidomide for an additional 8 weeks; all responders were followed up for a minimum of 52 weeks.

RESULTS: Twenty-six children with refractory UC were randomized to thalidomide or placebo. Clinical remission at week 8 was achieved by significantly more children treated with thalidomide {10/12 (83.3\%) versus 2/11 (18.8\%); risk ratio, 4.5 (95\% confidence interval [CI], 1.2-16.4); P = 0.005; number needed to treat, 1.5}. Of the nonresponders to placebo who were switched to thalidomide, 8 of 11 (72.7\%) subsequently reached remission at week 8 (risk ratio, 4.0 [95\% CI, 1.1-14.7]; number needed to treat, 2.45; P = 0.01). Clinical remission in the thalidomide group was 135.0 weeks (95\% CI, 32-238), compared with 8.0 weeks (95\% CI, 2.4-13.6) in the placebo group (P < 0.0001). Cumulative incidence of severe adverse events was 3.1 per 1000 patient-weeks. Peripheral neuropathy and amenorrhea were the most frequent adverse events.

CONCLUSIONS: In this pilot randomized controlled trial on cases of UC refractory to immunosuppressive therapy, thalidomide compared with placebo resulted in improved clinical remission at 8 weeks of treatment and in longer term maintenance of remission. These findings require replication in larger clinical studies evaluating both thalidomide efficacy and safety.

}, issn = {1536-4844}, doi = {10.1097/MIB.0000000000000437}, author = {Lazzerini, Marzia and Martelossi, Stefano and Magazz{\`u}, Giuseppe and Pellegrino, Salvatore and Lucanto, Maria Cristina and Barabino, Arrigo and Calvi, Angela and Arrigo, Serena and Lionetti, Paolo and Lorusso, Monica and Mangiantini, Francesca and Fontana, Massimo and Zuin, Giovanna and Palla, Gabriella and Maggiore, Giuseppe and Bramuzzo, Matteo and Pellegrin, Maria Chiara and Maschio, Massimo and Villanacci, Vincenzo and Manenti, Stefania and Decorti, Giuliana and De Iudicibus, Sara and Paparazzo, Rossella and Montico, Marcella and Ventura, Alessandro} } @article {8037, title = {Hypoxaemia as a Mortality Risk Factor in Acute Lower Respiratory Infections in Children in Low and Middle-Income Countries: Systematic Review and Meta-Analysis.}, journal = {PLoS One}, volume = {10}, year = {2015}, month = {2015}, pages = {e0136166}, abstract = {

OBJECTIVE: To evaluate the association between hypoxaemia and mortality from acute lower respiratory infections (ALRI) in children in low- and middle-income countries (LMIC).

DESIGN: Systematic review and meta-analysis.

STUDY SELECTION: Observational studies reporting on the association between hypoxaemia and death from ALRI in children below five years in LMIC.

DATA SOURCES: Medline, Embase, Global Health Library, Lilacs, and Web of Science to February 2015.

RISK OF BIAS ASSESSMENT: Quality In Prognosis Studies tool with minor adaptations to assess the risk of bias; funnel plots and Egger{\textquoteright}s test to evaluate publication bias.

RESULTS: Out of 11,627 papers retrieved, 18 studies from 13 countries on 20,224 children met the inclusion criteria. Twelve (66.6\%) studies had either low or moderate risk of bias. Hypoxaemia defined as oxygen saturation rate (SpO2) <90\% associated with significantly increased odds of death from ALRI (OR 5.47, 95\% CI 3.93 to 7.63) in 12 studies on 13,936 children. An Sp02 <92\% associated with a similar increased risk of mortality (OR 3.66, 95\% CI 1.42 to 9.47) in 3 studies on 673 children. Sensitivity analyses (excluding studies with high risk of bias and using adjusted OR) and subgroup analyses (by: altitude, definition of ALRI, country income, HIV prevalence) did not affect results. Only one study was performed on children living at high altitude.

CONCLUSIONS: The results of this review support the routine evaluation of SpO2 for identifying children with ALRI at increased risk of death. Both a Sp02 value of 92\% and 90\% equally identify children at increased risk of mortality. More research is needed on children living at high altitude. Policy makers in LMIC should aim at improving the regular use of pulse oximetry and the availability of oxygen in order to decrease mortality from ALRI.

}, issn = {1932-6203}, doi = {10.1371/journal.pone.0136166}, author = {Lazzerini, Marzia and Sonego, Michela and Pellegrin, Maria Chiara} } @article {8054, title = {Risk factors for mortality from acute lower respiratory infections (ALRI) in children under five years of age in low and middle-income countries: a systematic review and meta-analysis of observational studies.}, journal = {PLoS One}, volume = {10}, year = {2015}, month = {2015}, pages = {e0116380}, abstract = {

OBJECTIVE: To evaluate risk factors for death from acute lower respiratory infections (ALRI) in children in low- and middle-income countries.

DESIGN: Systematic review and meta-analysis.

STUDY SELECTION: Observational studies reporting on risk factors for death from ALRI in children below five years in low- and middle income countries.

DATA SOURCES: Medline, Embase, Global Health Library, Lilacs, and Web of Science to January 2014.

RISK OF BIAS ASSESSMENT: Quality In Prognosis Studies tool with minor adaptations to assess the risk of bias; funnel plots and Egger{\textquoteright}s test to evaluate publication bias.

RESULTS: Out of 10,655 papers retrieved, 77 studies from 39 countries (198,359 children) met the inclusion criteria. Host and disease characteristics more strongly associated with ALRI mortality were: diagnosis of very severe pneumonia as per WHO definition (odds ratio 9.42, 95\% confidence interval 6.37-13.92); age below two months (5.22, 1.70-16.03); diagnosis of Pneumocystis Carinii (4.79, 2.67-8.61), chronic underlying diseases (4.76, 3.27-6.93); HIV/AIDS (4.68, 3.72-5.90); and severe malnutrition (OR 4.27, 3.47-5.25). Socio-economic and environmental factors significantly associated with increased odds of death from ALRI were: young maternal age (1.84, 1.03-3.31); low maternal education (1.43, 1.13-1.82); low socio-economic status (1.62, 1.32-2.00); second-hand smoke exposure (1.52, 1.20 to 1.93); indoor air pollution (3.02, 2.11-4.31). Immunisation (0.46, 0.36-0.58) and good antenatal practices (0.50, 0.31-0.81) were associated with decreased odds of death.

CONCLUSIONS: Host and disease characteristics as well as socio-economic and environmental determinants affect the risk of death from ALRI in children. Together with the prevention and treatment of chronic diseases, interventions to modify underlying risk factors such as poverty, lack of female education, and poor environmental conditions, should be considered among the strategies to reduce ALRI mortality in children in low- and middle-income countries.

}, keywords = {Child, Preschool, Developing Countries, Environmental Exposure, Humans, Infant, Infant, Newborn, Observational Studies as Topic, Poverty, Respiratory Tract Infections, Risk Factors, Survival Analysis}, issn = {1932-6203}, doi = {10.1371/journal.pone.0116380}, author = {Sonego, Michela and Pellegrin, Maria Chiara and Becker, Genevieve and Lazzerini, Marzia} } @article {1873, title = {Acute febrile cholestatic jaundice in children: keep in mind Kawasaki disease.}, journal = {J Pediatr Gastroenterol Nutr}, volume = {55}, year = {2012}, month = {2012 Oct}, pages = {380-3}, abstract = {

Kawasaki disease (KD) is characterized by persistent fever in addition to 4 of 5 signs of mucocutaneous inflammation. Although gastrointestinal involvement does not belong to the classic diagnostic criteria, it has been often associated with KD onset. We reviewed patients who were admitted for febrile cholestatic jaundice between 2003 and 2010 in 2 tertiary pediatric care centers. KD was the second most frequent cause (21\%) after viral infections. Considering the relative high frequency of this condition, a high index of suspicion of KD should be maintained in patients presenting with febrile cholestatic jaundice.

}, keywords = {Child, Child, Preschool, Diagnosis, Differential, Female, Fever, Humans, Infant, Jaundice, Obstructive, Male, Mucocutaneous Lymph Node Syndrome, Virus Diseases}, issn = {1536-4801}, doi = {10.1097/MPG.0b013e31825513de}, author = {Taddio, Andrea and Pellegrin, Maria Chiara and Centenari, Chiara and Filippeschi, Irene Pellegrini and Ventura, Alessandro and Maggiore, Giuseppe} } @article {1770, title = {Acute cardiac valvular involvement in Kawasaki Disease.}, journal = {Clin Exp Rheumatol}, volume = {29}, year = {2011}, month = {2011 Jan-Feb}, pages = {S140}, keywords = {Adrenal Cortex Hormones, Child, Preschool, Female, Heart Valve Diseases, Humans, Immunoglobulins, Intravenous, Immunosuppressive Agents, Infant, Male, Mucocutaneous Lymph Node Syndrome, Treatment Outcome}, issn = {0392-856X}, author = {Pellegrin, Maria Chiara and Taddio, Andrea and Lepore, Loredana} }